SCHEMBL4421964

SCHEMBL4421964

COc1cc2c(N)ncnc2cc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.56
TLR9 Q9NR96 5/20 0.48
ACHE P22303 1/20 0.48
BACE1 P56817 1/20 0.48
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
PBRM1 Q86U86 1/20 0.48
TLR7 Q9NYK1 2/20 0.46
KIT P10721 2/20 0.46
EPHA2 P29317 1/20 0.45
KDR P35968 1/20 0.45
EPHB4 P54760 1/20 0.45
PDGFRB P09619 2/20 0.44
PDGFRA P16234 1/20 0.44
ENPP1 P22413 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2C P18825 1/20 0.43
ADRA1A P35348 1/20 0.43
KCNH2 Q12809 1/20 0.43
PIK3CD O00329 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30264759 0.82 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPIK3CGNSD2
SCHEMBL10058374 0.81 MAP4K4 (0.61) MAP4K4SMARCA2SMARCA4PBRM1KIT
SCHEMBL4424024 0.81 ACHE (0.60) MAP4K4ACHEBACE1KDR
SCHEMBL5828984 0.80 EPHA2 (0.50) TLR9TLR7EPHA2KDREPHB4
SCHEMBL906154 0.79 TLR9 (0.69) TLR9ACHEBACE1KITPDGFRB
SCHEMBL23726903 0.78 ACHE (0.67) ACHEBACE1KITPDGFRBPDGFRA
SCHEMBL21415489 0.78 ACHE (0.61) TLR9ACHEBACE1KITPDGFRB
SCHEMBL4424010 0.78 TRPA1 (0.46) MAP4K4TLR9TLR7KITEPHA2
SCHEMBL21045603 0.78 TRPC6 (0.56) MAP4K4TLR9SMARCA2SMARCA4PBRM1
SCHEMBL30419595 0.78 TRPC6 (0.56) MAP4K4TLR9SMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498335-B2 Method of producing an antiangiogenic or vascular permeability reducing effect ASTRAZENECA AB (CH) 2009-03-03 US disclosed
US-6806274-B1 IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS ASTRAZENECA UK LIMITED (GB) 2004-10-19 US disclosed
US-20030225111-A1 Therapy ASTRAZENECA AB (SE) 2003-12-04 US disclosed
EP-1272185-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2003-01-08 EP disclosed
WO-2002002534-A1 QUINAZOLINES WITH THERAPEUTIC USE ASTRAZENECA AB (SE) 2002-01-10 WO disclosed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225111-A1 Therapy VEGFA, AQP1, FLT1 MAP4K4 3090/4885TLR9 3261/4885ACHE 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.